All Posts Tagged With: "MYL"
(MYL) Mylan Incorporated – Bull of the Day
Mylan, Inc. (MYL) is one of the leading players in the US generics market. The company holds immense potential as many blockbuster drugs have begun to go off-patent and many more will lose patent exclusivity in the next few years. Moreover, we are encouraged by Mylan’s...
30Jan2012 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant...
29Dec2011 | vitalstocks | 0 comments | Continued(EU) Emerging Markets: The Way Forward
According to Irish orator, philosopher, & politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. —...
7Dec2011 | vitalstocks | 0 comments | Continued(PFE) Watson Pharmaceuticals Joins Pfizer for Generic Lipitor
November 30, 2011 was a big day for Pfizer, Inc. (PFE) with its blockbuster cholesterol drug, Lipitor, losing exclusivity in the US. With so many drugs losing exclusivity, why is the loss of exclusivity of Lipitor such a major event? Well, Lipitor has been a huge revenue generator...
6Dec2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Earns FDA Approval
Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food & Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb’s (BMY) drug Reyataz and...
5Dec2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Approved for Zinecard Generic
Mylan, Inc.’s (MYL) generic business was boosted further with the approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pharmacia & Upjohn’s Zinecard injection. Zinecard injection, which is a chemoprotective agent, recorded revenue of...
1Dec2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Settles with Novartis
Mylan, Inc. (MYL) recently announced a settlement agreement with Novartis (NVS) relating to the generic version of Novartis’ bioidentical estrogen therapy Vivelle-Dot. As a result of the resolution, the lawsuit filed by Novartis will be dismissed and Mylan can launch a generic...
28Nov2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Settles with Roche for Xeloda
Mylan Inc. (MYL) recently announced that it has entered into a settlement and license agreement with Roche (RHHBY) bringing an end to its ongoing litigation with the latter relating to Roche’s cancer drug Xeloda. Mylan was looking to launch a generic version of the drug which...
23Sep2011 | vitalstocks | 0 comments | Continued(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook
The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance...
23Sep2011 | vitalstocks | 0 comments | Continued(TEVA) Teva Pharmaceutical Industries Earns Favorable Court Ruling
Teva Pharmaceutical Industries Ltd. (TEVA) recently received a boost with the US District Court for the Southern District of New York issuing a favorable ruling related to the company’s patent infringement lawsuit against Novartis AG (NVS)/Momenta Pharmaceuticals, Inc. (MNTA)...
1Sep2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Analyst Reaffirms Shares at Neutral
We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $19.00 following an appraisal of second quarter 2011 financial results. Mylan’s second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus...
25Aug2011 | vitalstocks | 0 comments | Continued(MYL) Mylan and Endo Pharmaceuticals in Legal Tussle
Mylan Inc. (MYL) recently announced that Endo Pharmaceuticals (ENDP) filed a patent infringement lawsuit in connection with an abbreviated new drug application (ANDA) filed by Mylan with the US Food and Drug Administration (FDA) for the generic version of Endo’s acute migraine...
18Aug2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Beats Second Quarter Earnings on All Fronts
Mylan Inc.’s (MYL) second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents as well as the year-ago earnings of 37 cents per share. Earnings growth was driven by increase in generics revenue and improved...
27Jul2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Gets HIV Rights from Gilead
Mylan, Inc. (MYL) recently announced that its Indian subsidiary Matrix Laboratories has been granted future rights to produce and sell generic versions of three investigational HIV therapies of Gilead Sciences, Inc. (GILD), if and when approved. The agreement aims to expand access...
14Jul2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Expands HIV Drug’s Reach
Recently, Bristol-Myers Squibb Company (BMY) inked a deal with Mylan Inc. (MYL) to expand the market for its HIV drug Reyataz (atazanavir sulfate). The deal allows Matrix to develop and sell the generic version of the HIV therapy in the Indian and sub-Saharan African markets. Apart...
30Jun2011 | vitalstocks | 0 comments | Continued(MYL) Trial Date for Teva Pharmaceuticals / Mylan Dispute
Mylan Inc. (MYL) received some good news recently when a US District court denied Teva Pharmaceuticals Industries’ (TEVA) motion for a summary judgment, finding no inequitable conduct in the Copaxone infringement lawsuit. The court has ordered that the trial for inequitable...
22Jun2011 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Stock Outlook – June 2011 – Industry Outlook
Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between...
14Jun2011 | vitalstocks | 0 comments | Continued(ENDP) Endo Pharmaceuticals Evenly Poised
We are maintaining our Neutral stance on Endo Pharmaceuticals (ENDP) with a target price of $44.00. Headquartered in Chadds Ford, Pennsylvania and founded in 1997, Endo Pharma is a specialty healthcare solutions company. The company, which operates in the US, reports results...
30May2011 | vitalstocks | 0 comments | Continued(MDCO) The Medicines Company Analyst Reiterates Neutral on Shares
We recently reiterated a Neutral recommendation on The Medicines Company (MDCO), which carries a Zacks #3 Rank (short-term Hold rating). The Medicines Company reported a first-quarter profit of 60 cents per share, well above the Zacks Consensus Estimate of 39 cents and the year-ago...
27May2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Launches New Generic Pharmaceuticals
Mylan Inc.’s (MYL) generic portfolio continued to be boosted with the launch of the generic version of Xanodyne Pharmaceutical’s pain reliever Roxicodone. The generic has been launched under a development and supply agreement with Coastal Pharmaceuticals. The product recorded...
27May2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Launches Generic Drugs
MylanInc. (MYL) recently launched its generic version of Ista Pharmaceuticals Inc’s (ISTA) Xibrom ophthalmic solution, used for the treatment of inflammation in patients who have undergone a cataract extraction operation. The generic has been launched under a development and...
21May2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Meets Analyst Estimates – Sales Upbeat
Mylan Inc.’s (MYL) first quarter 2011 earnings (excluding special items) of 44 cents per share were in line with the Zacks Consensus Estimate. A higher quarterly tax rate, increased share count and pricing pressure in Europe offset the increase in generics revenue in North...
3May2011 | vitalstocks | 0 comments | Continued(AZN) AstraZeneca Drug Vandetanib Earns FDA Approval
AstraZeneca (AZN) recently gained US Food and Drug Administration (FDA) approval for its orphan drug vandetanib for the treatment of non-operable (unresectable) locally advanced or metastatic medullary thyroid cancer (MTC). The approval, however, comes with a boxed warning and...
9Apr2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Analyst Maintains Neutral Rating on Shares
We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $23.00 after appraising fourth quarter and fiscal year 2010 financial results. Mylan’s fourth quarter 2010 earnings (excluding special items) of 45 cents per share were at par with the...
20Mar2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals Analyst Maintains Neutral Rating on Shares
We recently reaffirmed our Neutral stance on Watson Pharmaceuticals Inc. (WPI) following the release of fourth quarter and fiscal year 2010 financial results. Quarterly earnings of 93 cents per share were in line with the Zacks Consensus Estimate and 8 cents above the year-ago...
17Mar2011 | vitalstocks | 0 comments | Continued(JNJ) Pharmaceutical Industry Outlook – March 2011 – Industry Outlook
The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance...
2Mar2011 | vitalstocks | 0 comments | Continued(AMGN) Stock Market News for Dec 15, 2010 – Market News
On Tuesday, the markets closed almost flat after a muted view from the Federal Reserve about the economic recovery. However, stocks were helped marginally by the positive report on retail spending. The Dow Jones Industrial Average rose 0.4% to 11,476.54.The Standard & Poor’s...
15Dec2010 | vitalstocks | 0 comments | Continued(TEVA) Teva Pharmaceutical Industries Beats The Street on Earnings
Teva Pharmaceutical Industries’ (TEVA) third quarter earnings of $1.30 per American Depository Share (ADS) were above the Zacks Consensus Estimate of $1.27 and the year-ago earnings of 89 cents. Teva’s top-line performance remained strong with revenues increasing 19.7% to...
15Nov2010 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Industry Outlook – November 2010 – Industry Outlook
With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance...
15Nov2010 | vitalstocks | 0 comments | Continued(CEPH) Cephalon Reports Very Strong Quarterly Earnings
Cephalon, Inc. (CEPH) delivered another strong quarter with earnings coming at $2.14 per share, easily beating the Zacks Consensus Estimate of $1.79 and well above the year-ago earnings of $1.62. Strong revenues, a favorable product mix and the company’s continuing efforts...
1Nov2010 | vitalstocks | 0 comments | Continued